13 nov. L’hépatite virale constitue un problème de santé publique international, comparable à celui posé par d’autres grandes maladies transmissibles. VIH, hépatites virales et comorbidités: épidémiologie clinique et santé era: Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) CO3 . 29 nov. L’hépatite A est surveillée en France par la déclaration obligatoire . /Hepatites- virales/Hepatite-A/Comment-signaler-et-notifier-cette-maladie.
|Published (Last):||28 January 2017|
|PDF File Size:||3.37 Mb|
|ePub File Size:||8.21 Mb|
|Price:||Free* [*Free Regsitration Required]|
Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient. Can the “seek, test, treat, and retain” strategy be effective in France? Antiretroviral exposure and comorbidities in an aging HIV-infected population: Acute and chronic hepatitis E in patients infected with hepqtites immunodeficiency virus.
Agence Nationale de Recherches Sur le SIDA et les hepatites virales
Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIVinfected patients. Eur J Gastroenterol Hepatol.
HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: What’s new in ? Infection par le VIH et parcours de soin: Cancer risk in HIV-infected patients: Eur J Clin Pharmacol.
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy. Mandibular osteonecrosis and dental exfoliation after trigeminal zoster in an HIV-infected patient: Consequences on Chemotherapy Efficiency and Safety. Human immunodeficiency virus infection and non-small cell vieales cancer: An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy.
Changes over the past 10 years in France.
J Med Virol Hepatitis E virus infection in patients infected with the human immunodeficiency virus. Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription.
Discussion:Hépatite virale — Wikipédia
Impact on Tenofovir Ctrough but not on Renal Safety? Impact on tenofovir trough concentrations and renal safety. Risk factors of chronic kidney disease in HIV-infected patients. Br J Clin Pharmacol. The challenge of geriatric patients. Results of a large French prospective cohort.
Efficacy and safety of dolutegravir and rilpivirine dual therapy as 1 a simplification. Results from traditional regression modeling and causal approach in a large observational study. Mandibular osteonecrosis and dental exfoliation after trigeminal zoster in an HIV-infected patient.
HIV is associated with airway obstruction: Frailty in HIV infected people: Effectiveness and tolerance of single tablet versus once daily hepatitew tablet regimens as first-line antiretroviral therapy – Results from a large french multicenter cohort study. No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France.
Which antiretrovirals should be prescribed as first-line treatments? Results from a French prospective cohort. A Cross- Sectional Analysis.
Impact of tenofovir trough concentration. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV. The spectrum of malignancies in HIV-infected patients in in France: Renal impairment in patients virxles a tenofovir-cART regimen: From guidelines to clinical practice.
Scand J Infect Dis. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Linked in Viadeo Youtube Email. Antiretroviral therapy as a risk factor for chronic kidney disease: Formulaire de recherche Recherche. Aging, behavioral factors but not cART in a cross-sectional study. C Med Mal Infect.
Hépatites virales B et C | AP-HM
J Acquir Immune Defic Syndr. HIV, co-morbidities and co-medications. Evaluating hepatitew outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
Tipranavir in highly antiretroviral treatment-experienced patients: